Community Healthcare Trust (CHCT) 10-Q 1 Aug 23 2023 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2023	Jul. 26, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2023
Document Transition Report	false
Entity File Number	001-37401
Entity Registrant Name	Community Healthcare Trust Inc
Entity Incorporation, State or Country Code	MD
Entity Tax Identification Number	46-5212033
Entity Address, Address Line One	3326 Aspen Grove Drive
Entity Address, Address Line Two	Suite 150
Entity Address, City or Town	Franklin
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37067
City Area Code	615
Local Phone Number	771-3052
Title of 12(b) Security	Common stock, $0.01 par value per share
Trading Symbol	CHCT
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		26,559,075
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001631569
Current Fiscal Year End Date	--12-31

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Real estate properties
Land and land improvements	$ 127,433	$ 117,657
Buildings, improvements, and lease intangibles	859,231	825,257
Personal property	284	253
Total real estate properties	986,948	943,167
Less accumulated depreciation	(181,769)	(165,341)
Total real estate properties, net	805,179	777,826
Cash and cash equivalents	2,627	11,233
Restricted cash	1,049	835
Other assets, net	91,611	86,531
Total assets	900,466	876,425
Liabilities
Debt, net	368,127	352,997
Accounts payable and accrued liabilities	10,605	11,377
Other liabilities, net	16,409	15,237
Total liabilities	395,141	379,611
Commitments and contingencies
Stockholders' Equity
Preferred stock, $0.01 par value; 50,000 shares authorized; none issued and outstanding	0	0
Common stock, $0.01 par value; 450,000 shares authorized; 26,541 and 25,897 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively	265	259
Additional paid-in capital	657,057	625,136
Cumulative net income	80,797	81,142
Accumulated other comprehensive income	23,085	22,667
Cumulative dividends	(255,879)	(232,390)
Total stockholders’ equity	505,325	496,814
Total liabilities and stockholders' equity	$ 900,466	$ 876,425

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	50,000,000	50,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	450,000,000	450,000,000
Common stock, shares issued (in shares)	26,541,000	25,897,000
Common stock, shares outstanding (in shares)	26,541,000	25,897,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
REVENUES
Rental income		$ 26,764	$ 23,197	$ 52,892	$ 45,801
Other operating interest		1,046	852	2,094	1,729
Total revenue		27,810	24,049	54,986	47,530
EXPENSES
Property operating		4,786	4,062	9,659	8,153
General and administrative	[1]	3,787	3,610	19,992	6,926
Depreciation and amortization		9,219	8,077	18,237	16,019
Total expenses		17,792	15,749	47,888	31,098
INCOME BEFORE INCOME TAXES AND OTHER ITEMS		10,018	8,300	7,098	16,432
Interest expense		(4,140)	(2,755)	(8,132)	(5,381)
Deferred income tax (expense) benefit		(50)	(16)	(85)	1
Interest and other income		749	55	774	56
Net income (loss)		$ 6,577	$ 5,584	$ (345)	$ 11,108
NET INCOME PER COMMON SHARE:
Net income (loss) per common share – basic (in dollars per share)		$ 0.24	$ 0.21	$ (0.07)	$ 0.41
Net income (loss) per common share – diluted (in dollars per share)		$ 0.24	$ 0.21	$ (0.07)	$ 0.41
Weighted average common shares outstanding - basic (in shares)		25,065	23,578	24,648	23,574
Weighted average common shares outstanding - diluted (in shares)		25,065	23,578	24,648	23,574
[1] (1) General and administrative expenses for the six months ended June 30, 2023 included stock-based compensation expense totaling approximately $16.0 million, including the accelerated amortization of stock-based compensation totaling approximately $11.8 million recognized upon the passing of our former CEO and President. General and administrative expenses for the six months ended June 30, 2022 included stock-based compensation expense totaling approximately $4.3 million. See Note 9.

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Stock-based compensation expense	$ 16,000	$ 4,300
Accelerated amortization of stock-based compensation	$ 11,799	$ 0

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Statement of Comprehensive Income [Abstract]
NET INCOME (LOSS)	$ 6,577	$ 5,584	$ (345)	$ 11,108
Other comprehensive income:
Increase in fair value of cash flow hedges	9,875	4,584	4,902	15,991
Reclassification for amounts recognized as interest expense	(2,474)	635	(4,484)	1,750
Total other comprehensive income	7,401	5,219	418	17,741
COMPREHENSIVE INCOME	$ 13,978	$ 10,803	$ 73	$ 28,849

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Preferred Stock	Common Stock	Additional Paid in Capital	Cumulative Net Income	Accumulated Other Comprehensive Income	Cumulative Dividends
Beginning balance (in shares) at Dec. 31, 2021		0
Beginning balance at Dec. 31, 2021	$ 462,112	$ 0	$ 250	$ 595,624	$ 59,123	$ (4,980)	$ (187,905)
Balance, beginning of period (in shares) at Dec. 31, 2021	24,983,000		24,983,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock, net of issuance costs	$ (299)			(299)
Stock-based compensation, net of forfeitures (in shares)			116,000
Stock-based compensation, net of forfeitures	4,307		$ 1	4,306
Increase in fair value of cash flow hedges	15,991					15,991
Reclassification for amounts recognized as interest expense	1,750					1,750
Net (loss) income	11,108				11,108
Dividends to common stockholders	(22,007)						(22,007)
Ending balance (in shares) at Jun. 30, 2022		0
Ending balance at Jun. 30, 2022	472,962	$ 0	$ 251	599,631	70,231	12,761	(209,912)
Balance, end of period (in shares) at Jun. 30, 2022			25,099,000
Beginning balance (in shares) at Dec. 31, 2021		0
Beginning balance at Dec. 31, 2021	$ 462,112	$ 0	$ 250	595,624	59,123	(4,980)	(187,905)
Balance, beginning of period (in shares) at Dec. 31, 2021	24,983,000		24,983,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock, net of issuance costs (in shares)	600,000
Ending balance (in shares) at Dec. 31, 2022	0	0
Ending balance at Dec. 31, 2022	$ 496,814	$ 0	$ 259	625,136	81,142	22,667	(232,390)
Balance, end of period (in shares) at Dec. 31, 2022	25,897,000		25,897,000
Beginning balance (in shares) at Mar. 31, 2022		0
Beginning balance at Mar. 31, 2022	$ 471,114	$ 0	$ 251	597,548	64,647	7,542	(198,874)
Balance, beginning of period (in shares) at Mar. 31, 2022			25,072,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock, net of issuance costs	(101)			(101)
Stock-based compensation, net of forfeitures (in shares)			27,000
Stock-based compensation, net of forfeitures	2,184			2,184
Increase in fair value of cash flow hedges	4,584					4,584
Reclassification for amounts recognized as interest expense	635					635
Net (loss) income	5,584				5,584
Dividends to common stockholders	(11,038)						(11,038)
Ending balance (in shares) at Jun. 30, 2022		0
Ending balance at Jun. 30, 2022	$ 472,962	$ 0	$ 251	599,631	70,231	12,761	(209,912)
Balance, end of period (in shares) at Jun. 30, 2022			25,099,000
Beginning balance (in shares) at Dec. 31, 2022	0	0
Beginning balance at Dec. 31, 2022	$ 496,814	$ 0	$ 259	625,136	81,142	22,667	(232,390)
Balance, beginning of period (in shares) at Dec. 31, 2022	25,897,000		25,897,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock, net of issuance costs (in shares)	485,000		485,000
Issuance of common stock, net of issuance costs	$ 16,851		$ 5	16,846
Stock-based compensation, net of forfeitures (in shares)			159,000
Stock-based compensation, net of forfeitures	16,039		$ 1	16,038
Shares withheld on vesting of stock-based compensation	(963)			(963)
Increase in fair value of cash flow hedges	4,902					4,902
Reclassification for amounts recognized as interest expense	(4,484)					(4,484)
Net (loss) income	(345)				(345)
Dividends to common stockholders	$ (23,489)						(23,489)
Ending balance (in shares) at Jun. 30, 2023	0	0
Ending balance at Jun. 30, 2023	$ 505,325	$ 0	$ 265	657,057	80,797	23,085	(255,879)
Balance, end of period (in shares) at Jun. 30, 2023	26,541,000		26,541,000
Beginning balance (in shares) at Mar. 31, 2023		0
Beginning balance at Mar. 31, 2023	$ 494,515	$ 0	$ 263	648,384	74,220	15,684	(244,036)
Balance, beginning of period (in shares) at Mar. 31, 2023			26,274,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock, net of issuance costs (in shares)			236,000
Issuance of common stock, net of issuance costs	7,945		$ 2	7,943
Stock-based compensation, net of forfeitures (in shares)			31,000
Stock-based compensation, net of forfeitures	1,693			1,693
Shares withheld on vesting of stock-based compensation	(963)			(963)
Increase in fair value of cash flow hedges	9,875					9,875
Reclassification for amounts recognized as interest expense	(2,474)					(2,474)
Net (loss) income	6,577				6,577
Dividends to common stockholders	$ (11,843)						(11,843)
Ending balance (in shares) at Jun. 30, 2023	0	0
Ending balance at Jun. 30, 2023	$ 505,325	$ 0	$ 265	$ 657,057	$ 80,797	$ 23,085	$ (255,879)
Balance, end of period (in shares) at Jun. 30, 2023	26,541,000		26,541,000

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Parenthetical) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Statement of Stockholders' Equity [Abstract]
Dividends to common stockholders, per share (in dollars per share)	$ 0.4500	$ 0.4400	$ 0.8975	$ 0.8775

CONDENSED CONSOLIDATED STATEM_6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
OPERATING ACTIVITIES
Net (loss) income	$ (345)	$ 11,108
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization	18,237	16,019
Other amortization	508	419
Stock-based compensation	4,239	4,307
Accelerated amortization of stock-based compensation	11,799	0
Straight-line rent receivable	(1,737)	(1,737)
Net gain from insurance recovery on casualty loss	(706)	0
Deferred income tax expense (benefit)	85	(1)
Changes in operating assets and liabilities:
Other assets	(1,853)	(782)
Accounts payable and accrued liabilities	(233)	263
Other liabilities	(620)	(77)
Net cash provided by operating activities	29,374	29,519
INVESTING ACTIVITIES
Acquisitions of real estate	(39,712)	(28,671)
Funding of notes receivable	(1,985)	(3,000)
Proceeds from the repayment of notes receivable	2,255	1,500
Insurance proceeds from casualty loss	2,273	0
Capital expenditures on existing real estate properties	(7,884)	(3,648)
Net cash used in investing activities	(45,053)	(33,819)
FINANCING ACTIVITIES
Net borrowings on revolving credit facility	15,000	26,000
Mortgage note repayments	(63)	(69)
Dividends paid	(23,489)	(22,007)
Proceeds from issuance of common stock	16,944	0
Taxes paid on behalf of employees and shares withheld upon share vestings	(964)	0
Equity issuance costs	(141)	(133)
Net cash provided by financing activities	7,287	3,791
Decrease in cash and cash equivalents and restricted cash	(8,392)	(509)
Cash and cash equivalents and restricted cash, beginning of period	12,068	2,867
Cash and cash equivalents and restricted cash, end of period	3,676	2,358
Supplemental Cash Flow Information:
Interest paid (net of capitalized interest)	7,868	5,053
Invoices accrued for construction, tenant improvement and other capitalized costs	3,776	1,395
Reclassification of registration statement costs incurred in prior year to equity issuance costs	91	221
Increase in fair value of cash flow hedges	4,902	15,991
Income taxes paid	69	42
Capitalized interest	$ 349	$ 364

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Business Overview Community Healthcare Trust Incorporated (the ‘‘Company’’, ‘‘we’’, ‘‘our’’) was organized in the State of Maryland on March 28, 2014. The Company is a fully-integrated healthcare real estate company that owns and acquires real estate properties that are leased to hospitals, doctors, healthcare systems or other healthcare service providers. As of June 30, 2023, the Company had investments of approximately $991.2 million in 184 real estate properties (including a portion of one property accounted for as a sales-type lease with a gross amount totaling approximately $3.0 million and one property classified as an asset held for sale with a gross amount totaling approximately $1.3 million (see Note 10 – Other Assets, net and Note 4 – Real Estate Acquisitions and Dispositions, respectively)). The properties are located in 34 states, totaling approximately 4.0 million square feet in the aggregate and were approximately 91.7% leased at June 30, 2023 with a weighted average remaining lease term of approximately 7.1 years. Any references to square footage, property count, or occupancy percentages, and any amounts derived from these values in these notes to the Condensed Consolidated Financial Statements, are outside the scope of our independent registered public accounting firm's review. Basis of Presentation The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. This interim financial information should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. This interim financial information does not necessarily represent or indicate what the operating results will be for the year ending December 31, 2023. All intercompany accounts and transactions have been eliminated. Use of Estimates in the Condensed Consolidated Financial Statements Preparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results may materially differ from those estimates. Cash and Cash Equivalents and Restricted Cash Cash and cash equivalents includes short-term investments with original maturities of three months or less when purchased. Restricted cash consists of amounts held by the lender of our mortgage note payable to provide for future real estate tax, insurance expenditures and tenant improvements related to one property. The carrying amounts approximate fair value due to the short term maturity of these investments. The following table provides a reconciliation of cash and cash equivalents and restricted cash: Balance as of June 30, (Dollars in thousands) 2023 2022 Cash and cash equivalents $ 2,627 $ 1,699 Restricted cash 1,049 659 Cash, cash equivalents and restricted cash $ 3,676 $ 2,358 Income Taxes The Company has elected to be taxed as a real estate investment trust ("REIT"), as defined under the Internal Revenue Code of 1986, as amended (the "Code"). The Company and two subsidiaries have also elected for those

Real Estate Properties

Real Estate Properties	6 Months Ended
	Jun. 30, 2023
Real Estate [Abstract]
Real Estate Properties	REAL ESTATE PROPERTIES As of June 30, 2023, we had investments of approximately $991.2 million in 184 real estate properties (including a portion of one property accounted for as a sales-type lease with a gross amount totaling approximately $3.0 million and one property classified as held for sale with a gross amount totaling approximately $1.3 million). The Company's investments are diversified by property type, geographic location, and tenant as shown in the following tables: Property Type # of Properties Gross Investment Medical Office Building 85 $ 390,389 Inpatient Rehabilitation Facilities 7 151,234 Acute Inpatient Behavioral 5 130,410 Specialty Centers 37 119,865 Physician Clinics 30 86,602 Surgical Centers and Hospitals 10 52,762 Behavioral Specialty Facilities 9 45,019 Long-term Acute Care Hospitals 1 14,937 Total 184 $ 991,218 State # of Properties Gross Investment Texas 16 $ 138,913 Illinois 16 121,755 Ohio 25 110,285 Florida 22 96,249 Pennsylvania 13 42,408 All Others 92 481,608 Total 184 $ 991,218 Primary Tenant # of Properties Gross Investment Lifepoint Health (1) 5 $ 82,337 US HealthVest 3 77,964 GenesisCare 9 31,047 All Others 167 799,870 Total 184 $ 991,218 ____________ (1) During the first quarter of 2023, Everest Rehabilitation assigned its leases to Lifepoint Health on four properties in which the Company had a gross investment totaling $80.7 million at June 30, 2023. GenesisCare Bankruptcy On June 1, 2023, GenesisCare and certain of its affiliates ("GenesisCare") filed voluntary petitions for reorganization under Chapter 11 of the U.S. Bankruptcy Code. On June 27, 2023, the U.S. Bankruptcy Court for the Southern District of Texas approved GenesisCare’s request to reject certain unexpired real property leases including one lease of approximately 11,000 square feet with CHCT North Carolina, LLC, a subsidiary of the Company. At June 30, 2023, GenesisCare was the sole tenant in seven of our properties and a tenant in two of our multi-tenanted properties, representing approximately 3.1% of our gross real estate properties, or approximately 119,000 square feet. Other than the one rejected lease noted above, GenesisCare has met substantially all of its lease payment obligations due to the Company through July 2023. The Company has engaged counsel to monitor the GenesisCare bankruptcy progress and any additional potential impacts to the Company.

Real Estate Leases

Real Estate Leases	6 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Real Estate Leases	REAL ESTATE LEASES Lessor Accounting The Company’s properties are generally leased pursuant to non-cancelable, fixed-term operating leases with expiration dates through 2042. The Company’s leases generally require the lessee to pay minimum rent, with fixed rent renewal terms or increases based on a Consumer Price Index and may also include additional rent, which may include the reimbursement of taxes (including property taxes), insurance, maintenance and other operating costs associated with the leased property. Some leases provide the lessee, during the term of the lease, with an option or right of first refusal to purchase the leased property. Some leases also allow the lessee to renew or extend their lease term or in some cases terminate their lease, based on conditions provided in the lease. Future minimum lease payments under the non-cancelable operating leases due to the Company for the years ending December 31, as of June 30, 2023, are as follows (in thousands): 2023 (six months ended December 31) $ 46,294 2024 89,080 2025 82,644 2026 72,506 2027 66,194 2028 and thereafter 343,830 $ 700,548 Rental income is recognized as earned over the life of the lease agreement on a straight-line basis when collection of rental payments over the term of the lease is probable. Straight-line rent included in rental income was approximately $0.8 million and $0.9 million, respectively, for the three months ended June 30, 2023 and 2022, and was approximately $1.7 million for each of the six months ended June 30, 2023 and 2022. Purchase Option Provisions Certain of the Company's leases provide the lessee with a purchase option or a right of first refusal to purchase the leased property. The purchase option provisions generally allow the lessee to purchase the leased property at fair value or at an amount greater than the Company's gross investment in the leased property at the time of the purchase. At June 30, 2023, the Company had an aggregate gross investment of approximately $43.3 million in 12 real estate properties with purchase options exercisable at June 30, 2023 that had not been exercised. Sales-type Lease The Company has a portion of one property accounted for as a sales-type lease with a gross amount totaling approximately $3.0 million included in other assets, net on the Company's Condensed Consolidated Balance Sheets. Future lease payments due to the Company under this lease for the years ending December 31, as of June 30, 2023, are as follows (in thousands): 2023 (six months ended December 31) $ 170 2024 346 2025 356 2026 367 2027 378 2028 and thereafter 5,210 Total undiscounted lease receivable 6,827 Discount (3,794) Lease receivable $ 3,033 The Company recognized interest income of approximately $0.1 million during each of the three months ended June 30, 2023 and 2022 and recognized interest income of approximately $0.2 million during each of the six months ended June 30, 2023 and 2022 related to this lease which is included in other operating interest on the Company's Consolidated Statements of Income. Lessee Accounting At June 30, 2023, the Company was obligated, as the lessee, under four non-prepaid ground leases accounted for as operating leases with expiration dates, including renewal options, through 2076, and two non-prepaid ground leases accounted for as financing leases with expiration dates through 2109, including renewal options. Any rental increases related to the Company's ground leases are generally either stated or based on the Consumer Price Index. The Company's future lease payments under these non-prepaid ground leases were as follows (in thousands): Operating Financing 2023 (six months ended December 31) $ 21 $ 70 2024 43 154 2025 44 154 2026 44 154 2027 45 154 2028 and thereafter 1,148 6,956 Total undiscounted lease payments 1,345 7,642 Discount (565) (4,364) Lease liabilities $ 780 $ 3,278 The following table discloses other information regarding the ground leases. Three Months Ended 2023 2022 Operating leases: Weighted-average remaining lease term in years (including renewal options) 35.7 36.4 Weighted-average discount rate 4.0 % 4.0 % Financing leases: Weighted-average remaining lease term in years (including renewal options) 40.3 36.5 Weighted-average discount rate 4.2 % 4.1 %

Real Estate Acquisitions And Di

Real Estate Acquisitions And Dispositions	6 Months Ended
	Jun. 30, 2023
Business Combination and Asset Acquisition [Abstract]
Real Estate Acquisitions and Dispositions	REAL ESTATE ACQUISITIONS AND DISPOSITIONS Acquisitions During the second quarter of 2023, the Company acquired three real estate properties and one land parcel. Upon acquisition, the properties were 98.3% leased in the aggregate with lease expirations through 2033. Amounts reflected in revenues and net income for these properties for the three months ended June 30, 2023 were approximately $0.1 million and $32,000, respectively, and transaction costs totaling approximately $0.4 million were capitalized relating to these property acquisitions. During the first quarter of 2023, the Company acquired seven real estate properties. Upon acquisition, the properties were 100.0% leased in the aggregate with lease expirations through 2031. Amounts reflected in revenues and net income for these properties for the six months ended June 30, 2023 were approximately $1.3 million and $0.3 million, respectively, and transaction costs totaling approximately $0.4 million were capitalized relating to these property acquisitions. The following table summarizes our property acquisitions for the six months ended June 30, 2023: Location Property Type (1) Date Purchase Cash Real Estate Other (2) Square Footage (000's) (000's) (000's) (000's) LaGrange, GA MOB 01/18/23 $ 8,007 $ 8,087 $ 8,118 $ (31) 55,310 West Point, GA MOB 01/18/23 811 819 822 (3) 5,600 Canton, OH MOB 01/30/23 3,669 3,706 4,287 (581) 27,920 Scranton, PA MOB 02/23/23 1,957 2,165 2,317 (152) 22,743 Scranton, PA MOB 02/23/23 2,207 2,366 2,340 26 15,768 LaGrange, GA MOB 03/06/23 6,469 6,458 6,622 (164) 31,473 LaGrange, GA MOB 03/06/23 249 294 300 (6) 2,972 Lakeland, FL Land 04/03/23 838 845 846 (1) — Hermitage, PA MOB 05/04/23 4,218 4,382 4,529 (147) 25,982 San Antonio, TX MOB 05/22/23 2,772 2,783 3,031 (248) 12,376 Clinton, MD MOB 06/21/23 7,850 7,807 7,867 (60) 37,344 $ 39,047 $ 39,712 $ 41,079 $ (1,367) 237,488 (1) MOB - Medical Office Building (2) Includes other assets acquired, liabilities assumed, and above and below-market intangibles recognized at acquisition. The following table summarizes the relative fair values of the assets acquired and liabilities assumed in the property acquisitions for the six months ended June 30, 2023. Relative Estimated (in thousands) (in years) Land and land improvements $ 10,051 6.9 Building and building improvements 25,427 23.6 Intangibles: At-market lease intangibles 5,601 3.8 Above-market lease intangibles 481 3.6 Below-market lease intangibles (1,644) 5.9 Total intangibles 4,438 Accounts payable, accrued liabilities and other liabilities assumed (282) Accounts receivable and other assets acquired 242 Prorated rent, interest and operating expense reimbursement amounts collected (164) Total cash consideration $ 39,712 Asset Held for Sale The Company incurred property damage due to vandalism at a property in Houston, Texas which was covered by our insurance policies. The Company estimated the fair value of the damaged property and recorded a casualty loss, for the difference between the estimated fair value less costs to sale and the insurance proceeds received. The Company determined that the estimated amount of the casualty loss was approximately $1.6 million and received insurance proceeds totaling $2.3 million, resulting in a net casualty gain of approximately $0.7 million which was included in Interest and other income on the Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2023. At June 30, 2023, the Company committed to a plan to dispose of the property in Houston, Texas and classified the property as an asset held for sale totaling approximately $1.3 million which was included in Other assets, net and classified liabilities related to the property as liabilities held for sale totaling approximately $56,000 which were included in Other liabilities, net on the Condensed Consolidated Balance Sheet.

Debt, net

Debt, net	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Debt, net	DEBT, NET The table below details the Company's debt as of June 30, 2023 and December 31, 2022. Balance as of (Dollars in thousands) June 30, 2023 December 31, 2022 Maturity Dates Credit Facility: Revolving Credit Facility $ 15,000 $ — 3/26 A-3 Term Loan, net 74,670 74,609 3/26 A-4 Term Loan, net 124,465 124,409 3/28 A-5 Term Loan, net 149,124 149,059 3/30 Mortgage Note Payable, net 4,868 4,920 5/24 $ 368,127 $ 352,997 On December 14, 2022, Community Healthcare Trust Incorporated, as borrower, entered into a first amendment (the "First Amendment") to the third amended and restated credit agreement (the "Credit Facility") by and among Community Healthcare Trust Incorporated, as borrower, the several banks and financial institutions party thereto as lenders, and Truist Bank, as administrative agent. The First Amendment amended the Credit Facility to, among other things, (i) establish a new seven-year and three-month term loan facility in the aggregate principal amount of $150.0 million (the "A-5 Term Loan"), which matures on March 14, 2030 and (ii) replace LIBOR as a benchmark interest rate for loans under the Credit Facility with SOFR. The proceeds from the A-5 Term Loan were used in part to repay the seven-year term loan facility in the aggregate principal amount of $50.0 million (the "A-2 Term Loan") which was set to mature on March 29, 2024. The Credit Facility allows the Company to borrow, through the accordion feature, up to $700.0 million, including the ability to add and fund incremental term loans. The Company's material subsidiaries are guarantors of the obligations under the Credit Facility. The Credit Facility provides for a $150.0 million Revolving Credit Facility and $350.0 million in term loans (the "Term Loans"). The Revolving Credit Facility matures on March 19, 2026 and includes one 12-month option to extend the maturity date, subject to the satisfaction of certain conditions. The Term Loans include a seven-year term loan facility in the aggregate principal amount of $75.0 million (the "A-3 Term Loan"), which matures on March 29, 2026, a seven-year term loan facility in the aggregate principal amount of $125.0 million (the "A-4 Term Loan"), which matures on March 19, 2028, and the A-5 Term Loan, which matures on March 14, 2030. Under the First Amendment, amounts outstanding under the Revolving Credit Facility will bear interest at a floating rate based on the Company's option, on either: (i) adjusted term SOFR or adjusted daily simple SOFR plus 1.25% to 1.90% or (ii) a base rate plus 0.25% to 0.90% in each case, depending upon the Company’s leverage ratio. In addition, the Company is obligated to pay an annual fee equal to 0.20% of the amount of the unused portion of the Revolving Credit Facility if amounts borrowed are greater than 33.3% of the borrowing capacity under the Revolving Credit Facility and 0.25% of the unused portion of the Revolving Credit Facility if amounts borrowed are less than or equal to 33.3% of the borrowing capacity under the Revolving Credit Facility. The Company had $15.0 million outstanding under the Revolving Credit Facility with a weighted average interest rate of 6.80% and a borrowing capacity remaining of $135.0 million at June 30, 2023. Under the First Amendment, amounts outstanding under the Term Loans will bear interest at a floating rate that is based, at the Company's option, on either (i) adjusted term SOFR or adjusted daily SOFR plus 1.45% to 2.30% or (ii) a base rate plus 0.45% to 1.30%, in each case, depending upon the Company’s leverage ratio. The Company has entered into interest rate swaps to fix the interest rates on the Term Loans. See Note 6 – Derivative Financial Instruments for more details on the interest rate swaps. At June 30, 2023, the Company had $350.0 million outstanding under the Term Loans which had a fixed weighted average interest rate under the swaps of approximate ly 4.3% . The Company’s ability to borrow under the Credit Facility is subject to its ongoing compliance with a number of customary affirmative and negative covenants, including limitations with respect to liens, indebtedness, distributions, mergers, consolidations, investments, restricted payments and asset sales, as well as financial maintenance covenants. The Company was in compliance with its financial covenants under its Credit Facility as of June 30, 2023. Mortgage Note Payable

Derivative Financial Instrument

Derivative Financial Instruments	6 Months Ended
	Jun. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	DERIVATIVE FINANCIAL INSTRUMENTS Risk Management Objective of Using Derivatives The Company may use derivative financial instruments, including interest rate swaps, caps, options, floors and other interest rate derivative contracts, to hedge all or a portion of the interest rate risk associated with its borrowings. The principal objective of such arrangements is to minimize the risks and/or costs associated with the Company’s operating and financial structure as well as to hedge specific anticipated transactions. The Company does not intend to utilize derivatives for speculative or other purposes other than interest rate risk management. The use of derivative financial instruments carries certain risks, including the risk that the counterparties to these contractual arrangements are not able to perform under the agreements. To mitigate this risk, the Company only enters into derivative financial instruments with counterparties with high credit ratings and with major financial institutions with which the Company and its affiliates may also have other financial relationships. The Company does not anticipate that any of the counterparties will fail to meet their obligations. Cash Flow Hedges of Interest Rate Risk The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish these objectives, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. As of June 30, 2023, the Company had seventeen outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk for notional amounts totaling $350.0 million, including two forward-starting interest rate swaps for notional amounts totaling $50.0 million, which will not become effective until March 29, 2024. Tabular Disclosure of Fair Value of Derivative Instruments on the Balance Sheet The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the Condensed Consolidated Balance Sheets as of June 30, 2023 and December 31, 2022. Asset Derivatives Fair Value at Liability Derivatives Fair Value at (Dollars in thousands) June 30, 2023 December 31, 2022 Balance Sheet Classification June 30, 2023 December 31, 2022 Balance Sheet Classification Interest rate swaps $ 23,085 $ 22,667 Other assets, net $ — $ — Other liabilities, net The changes in the fair value of derivatives designated and that qualify as cash flow hedges are recorded in accumulated other comprehensive income ("AOCI") and are subsequently reclassified to interest expense in the period that the hedged forecasted transaction affects earnings. Amounts reported in AOCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s Term Loans. During the next twelve months, the Company estimates that an additional $10.5 million will be reclassified from AOCI as a decrease to interest expense. Tabular Disclosure of the Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income The table below details the location in the financial statements of the gain or loss recognized on interest rate derivatives designated as cash flow hedges for the three and six months ended June 30, 2023 and 2022. Three Months Ended Six Months Ended (Dollars in thousands) 2023 2022 2023 2022 Amount of unrealized gain recognized in OCI on derivatives $ 9,875 $ 4,584 $ 4,902 $ 15,991 Amount of (gain) loss reclassified from AOCI into interest expense $ (2,474) $ 635 $ (4,484) $ 1,750 Total interest expense presented in the Condensed Consolidated Statements of Operations in which the effects of the cash flow hedges are recorded $ 4,140 $ 2,755 $ 8,132 $ 5,381 Tabular Disclosures of Offsetting Derivatives The tables below present a gross presentation, the effects of offsetting, and a net presentation of the Company's derivatives as of June 30, 2023 and December 31, 2022. The net amounts of derivative assets or liabilities can be reconciled to the tabular disclosure of fair value. The tabular disclosure of fair value provides the location that derivative assets and liabilities are presented on the Condensed Consolidated Balance Sheets. Offsetting of Derivative Assets (as of June 30, 2023) Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets (In thousands) Gross Amounts of Recognized Assets Gross Amounts Offset in the Condensed Consolidated Balance Sheet Net Amounts of Assets in the Condensed Consolidated Balance Sheets Financial Instruments Cash Collateral Received Net Amount Derivatives $ 23,085 $ — $ 23,085 $ — $ — $ 23,085 Offsetting of Derivative Liabilities (as of June 30, 2023) Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets (In thousands) Gross Amounts of Recognized Liabilities Gross Amounts Offset in the Condensed Consolidated Balance Sheet Net Amounts of Liabilities in the Condensed Consolidated Balance Sheets Financial Instruments Cash Collateral Received Net Amount Derivatives $ — $ — $ — $ — $ — $ — Offsetting of Derivative Assets (as of December 31, 2022) Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets (In thousands) Gross Amounts of Recognized Assets Gross Amounts Offset in the Condensed Consolidated Balance Sheet Net Amounts of Assets in the Condensed Consolidated Balance Sheets Financial Instruments Cash Collateral Received Net Amount Derivatives $ 22,667 $ — $ 22,667 $ — $ — $ 22,667 Offsetting of Derivative Liabilities (as of December 31, 2022) Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets (In thousands) Gross Amounts of Recognized Liabilities Gross Amounts Offset in the Condensed Consolidated Balance Sheet Net Amounts of Liabilities in the Condensed Consolidated Balance Sheets Financial Instruments Cash Collateral Received Net Amount Derivatives $ — $ — $ — $ — $ — $ — Credit-risk-related Contingent Features As of June 30, 2023, the Company did not have any derivatives in a net liability position. As of June 30, 2023, the Company had not posted any collateral related to these agreements and was not in breach of any agreement provisions. If the Company terminated these interest rate swaps or breached any of these provisions, it could have been required to settle its obligations under the agreements at their aggregate termination value.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Stockholders' Equity	STOCKHOLDERS' EQUITY Common Stock The following table provides a reconciliation of the beginning and ending common stock balances for the six months ended June 30, 2023 and for the year ended December 31, 2022: (In thousands) Six Months Ended Year Ended Balance, beginning of period 25,897 24,983 Issuance of common stock 485 600 Restricted stock issued 190 318 Restricted stock withheld and forfeited (31) (4) Balance, end of period 26,541 25,897 ATM Program The Company has an at-the-market offering program ("ATM Program"), with Piper Sandler & Co., Evercore Group L.L.C., Truist Securities, Inc., Regions Securities LLC, Robert W. Baird & Co. Incorporated, Fifth Third Securities, Inc. and Janney Montgomery Scott LLC, as sales agents (collectively, the “Agents”). Under the ATM Program, the Company may issue and sell shares of its common stock, having an aggregate gross sales price of up to $500.0 million. The shares of common stock may be sold from time to time through or to one or more of the Agents, as may be determined by the Company in its sole discretion, subject to the terms and conditions of the agreement and applicable law. The Company's activity under the ATM Program during the six months ended June 30, 2023 is detailed in the table below. As of June 30, 2023, the Company had approximately $461.5 million remaining that may be issued under the ATM Program. Three Months Ended Six Months Ended Shares issued ( in thousands ) 236 485 Net proceeds received ( in millions) (1) $8.0 $16.9 Average gross sales price per share $34.45 $35.60 ___________ (1) Net proceeds totaling $0.7 million were received on April 3, 2023 relating to shares sold and issued in March 2023.

Net Income (Loss) Per Common Sh

Net Income (Loss) Per Common Share	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Net Income (Loss) Per Common Share	NET INCOME (LOSS) PER COMMON SHARE The following table sets forth the computation of basic and diluted net income (loss) per common share for the three and six months ended June 30, 2023 and 2022, respectively. Three Months Ended Six Months Ended (In thousands, except per share data) 2023 2022 2023 2022 Net income (loss) $ 6,577 $ 5,584 $ (345) $ 11,108 Participating securities' share in earnings (550) (668) (1,373) (1,327) Net income (loss), less participating securities' share in earnings $ 6,027 $ 4,916 $ (1,718) $ 9,781 Weighted average Common Shares outstanding Weighted average Common Shares outstanding 26,358 25,087 26,202 25,074 Unvested restricted shares (1,293) (1,509) (1,554) (1,500) Weighted average Common Shares outstanding–Basic 25,065 23,578 24,648 23,574 Dilutive potential common shares — — — — Weighted average Common Shares outstanding –Diluted 25,065 23,578 24,648 23,574 Basic Net Income (Loss) per Common Share $ 0.24 $ 0.21 $ (0.07) $ 0.41 Diluted Net Income (Loss) per Common Share $ 0.24 $ 0.21 $ (0.07) $ 0.41

Stock Incentive Plan

Stock Incentive Plan	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Stock Incentive Plan	STOCK INCENTIVE PLAN A summary of the activity under the Company's 2014 Incentive Plan, as amended, for the three and six months ended June 30, 2023 and 2022 is included in the table below, as well as compensation expense recognized from the amortization of the value of shares over the applicable vesting periods. Three Months Ended Six Months Ended (Dollars and shares in thousands) 2023 2022 2023 2022 Stock-based awards, beginning of period 1,836 1,502 1,708 1,416 Stock in lieu of compensation 22 8 84 52 Stock awards 39 19 106 67 Total stock granted 61 27 190 119 Vested shares (1) (692) (17) (692) (22) Forfeited shares (2) — (3) (1) Stock-based awards, end of period 1,203 1,512 1,203 1,512 Amortization expense (1) $ 1,692 $ 2,184 $ 16,038 $ 4,307 ___________ (1) Amortization expense for the six months ended June 30, 2023 included the accelerated amortization totaling $11.8 million recognized during the three months ended March 31, 2023, upon the passing of our former CEO and President. These shares vested during the three months ended June 30, 2023. Accelerated Amortization and Vesting of Restricted Stock The Company's former CEO and President, Timothy Wallace, passed away in March 2023. At the time of his passing, Mr. Wallace had 624,725 shares of restricted stock that had not been fully amortized. In accordance with the terms of his employment agreement, the Company accelerated the unamortized remaining balance of deferred compensation related to his unvested shares and recognized an additional $11.8 million of amortization expense in the first quarter of 2023.

Other Assets, net

Other Assets, net	6 Months Ended
	Jun. 30, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Assets, net	OTHER ASSETS, NET Other assets, net on the Company's Condensed Consolidated Balance Sheets as of June 30, 2023 and December 31, 2022 are detailed in the table below. Balance as of (Dollars in thousands) June 30, 2023 December 31, 2022 Notes receivable $ 32,435 $ 32,705 Accounts and interest receivable 3,622 2,679 Straight-line rent receivable 17,176 15,429 Prepaid assets 1,685 980 Deferred financing costs, net 577 683 Leasing commissions, net 2,081 1,848 Deferred tax assets, net 221 306 Fair value of interest rate swaps 23,085 22,667 Above-market lease intangible assets, net 2,554 2,399 Sales-type lease receivable 3,033 3,035 Financing right-of-use asset 2,515 2,545 Asset held for sale 1,254 — Operating lease right-of-use assets 744 759 Other 629 496 $ 91,611 $ 86,531 The Company's notes receivable mainly included: • At June 30, 2023 and December 31, 2022, notes receivable included a $7.5 million and $9.0 million, respectively, term loan, secured by all assets and ownership interests in seven long-term acute care hospitals and one inpatient rehabilitation hospital owned by the borrower. The term loan will be repaid in equal monthly installments of $250,000 through the maturity date of December 31, 2025 and bears interest at 9% per annum. • At June 30, 2023 and December 31, 2022 , notes receivable included a term loan totaling $17.0 million and a revolving credit facility totaling $5.4 million and $5.0 million, respectively, secured by assets and ownership interests of six geriatric behavioral hospitals and affiliated companies all of which are co-borrowers on the loans. The term loan bears interest at 9% per annum, with interest only payments due initially and then equal monthly installments of principal payments due beginning March 3 1, 2024 . The term loan facility matures on Decem ber 31, 2032 . The revolving credit facility bears interest at 9% per annum and matures on December 31, 2025 . In addition, the Company has committed to fund, at the Company’s discretion, additional amounts, up to $5.0 million with interest at 9% per annum on any amount funded, that may be used by the borrower to pay existing liabilities of co-borrowers. The term loan, the revolving credit facility and the additional commitment all include a 3% per annum non-cash interest charge that is due and payable upon the earlier of the repayment or maturity of each note. • At June 30, 2023 and December 31, 2022, notes receivable included a $2.5 million and $1.7 million, respectively, revolving credit facility. Commencing on October 1, 2023, the revolving credit facility will be repaid in equal monthly installments of $40,000 through the maturity date of April 1, 2027. The revolving credit facility bears interest at 9% per annum, as well as a 3% per annum non-cash interest charge that is due and payable upon the earlier of the repayment or maturity of the note. The Company identified the borrowers of these notes as variable interest entities ("VIEs"), but management determined that the Company was not the primary beneficiary of the VIEs because we lack either directly or through related parties any material decision-making rights or control of the entities that impact the borrowers' economic performance. We are not obligated to provide support beyond our stated commitment to the borrowers, and accordingly our maximum exposure to loss as a result of this relationship is limited to the amount of our outstanding notes receivable. The VIEs that we have identified at June 30, 2023 are summarized in the table below. Classification Carrying Amount (in thousands) Maximum Exposure to Loss (in thousands) Note receivable (term loan) $ 7,500 $ 7,500 Note receivable (revolving credit facility) $ 5,435 $ 5,435 Note receivable (term loan) $ 17,000 $ 17,000 Note receivable (revolving credit facility) $ 2,500 $ 2,500

Other Liabilities, net

Other Liabilities, net	6 Months Ended
	Jun. 30, 2023
Other Liabilities Disclosure [Abstract]
Other Liabilities, net	OTHER LIABILITIES, NET Other liabilities, net on the Company's Condensed Consolidated Balance Sheets as of June 30, 2023 and December 31, 2022 are detailed in the table below. Balance as of (Dollars in thousands) June 30, 2023 December 31, 2022 Prepaid rent $ 5,579 $ 3,853 Security deposits 3,662 5,766 Below-market lease intangibles, net 2,439 1,075 Financing lease liability 3,278 3,279 Operating lease liability 780 786 Liabilities held for sale 56 — Other 615 478 $ 16,409 $ 15,237

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	FAIR VALUE OF FINANCIAL INSTRUMENTS The following methods and assumptions were used to estimate the fair value of each class of financial instruments for which it is practical to estimate the fair value. Cash and cash equivalents and restricted cash - The carrying amount approximates the fair value. Notes receivable - The fair value is estimated using cash flow analyses, based on an assumed market rate of interest or at a rate consistent with the rates on notes carried by the Company and are classified as level 2 inputs in the hierarchy. Borrowings under our Credit Facility - The carrying amount approximates the fair value because the borrowings are based on variable market interest rates. The fair value estimates were determined using level 2 inputs. Derivative financial instruments (Interest rate swaps) - The fair value is estimated using discounted cash flow techniques. These techniques incorporate primarily level 2 inputs. The market inputs are utilized in the discounted cash flow calculation considering the instrument’s term, notional amount, discount rate and credit risk. Significant inputs to the derivative valuation model for interest rate swaps are observable in active markets and are classified as level 2 inputs in the hierarchy. Mortgage note payable - The fair value is estimated using cash flow analyses which are based on an assumed market rate of interest or at a rate consistent with the rates on mortgage notes assumed by the Company and are classified as level 2 inputs in the hierarchy. The table below details the fair values and carrying values for our notes receivable, interest rate swaps, and mortgage note payable at June 30, 2023 and December 31, 2022, using level 2 inputs. June 30, 2023 December 31, 2022 (Dollars in thousands) Carrying Value Fair Value Carrying Value Fair Value Notes receivable $ 32,435 $ 32,604 $ 32,705 $ 32,716 Interest rate swap asset $ 23,085 $ 23,085 $ 22,667 $ 22,667 Mortgage note payable (principal amount) $ 4,884 $ 4,729 $ 4,947 $ 4,761

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	SUBSEQUENT EVENTS Dividend Declared On July 27, 2023, the Company’s Board of Directors declared a quarterly common stock dividend in the amount of $0.4525 per share. The dividend is payable on August 25, 2023 to stockholders of record on August 11, 2023. Acquisitions

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Pay vs Performance Disclosure
Net (loss) income	$ 6,577	$ 5,584	$ (345)	$ 11,108

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jun. 30, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. This interim financial information should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. This interim financial information does not necessarily represent or indicate what the operating results will be for the year ending December 31, 2023. All intercompany accounts and transactions have been eliminated.
Use of Estimates in the Condensed Consolidated Financial Statements	Use of Estimates in the Condensed Consolidated Financial Statements Preparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results may materially differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents and Restricted CashCash and cash equivalents includes short-term investments with original maturities of three months or less when purchased.
Restricted Cash	Restricted cash consists of amounts held by the lender of our mortgage note payable to provide for future real estate tax, insurance expenditures and tenant improvements related to one property. The carrying amounts approximate fair value due to the short term maturity of these investments.
Income Taxes	Income Taxes The Company has elected to be taxed as a real estate investment trust ("REIT"), as defined under the Internal Revenue Code of 1986, as amended (the "Code"). The Company and two subsidiaries have also elected for those

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Schedule of cash and cash equivalents	The following table provides a reconciliation of cash and cash equivalents and restricted cash: Balance as of June 30, (Dollars in thousands) 2023 2022 Cash and cash equivalents $ 2,627 $ 1,699 Restricted cash 1,049 659 Cash, cash equivalents and restricted cash $ 3,676 $ 2,358
Restrictions on cash and cash equivalents	The following table provides a reconciliation of cash and cash equivalents and restricted cash: Balance as of June 30, (Dollars in thousands) 2023 2022 Cash and cash equivalents $ 2,627 $ 1,699 Restricted cash 1,049 659 Cash, cash equivalents and restricted cash $ 3,676 $ 2,358

Real Estate Properties (Tables)

Real Estate Properties (Tables)	6 Months Ended
	Jun. 30, 2023
Real Estate [Abstract]
Schedule of real estate property investments	The Company's investments are diversified by property type, geographic location, and tenant as shown in the following tables: Property Type # of Properties Gross Investment Medical Office Building 85 $ 390,389 Inpatient Rehabilitation Facilities 7 151,234 Acute Inpatient Behavioral 5 130,410 Specialty Centers 37 119,865 Physician Clinics 30 86,602 Surgical Centers and Hospitals 10 52,762 Behavioral Specialty Facilities 9 45,019 Long-term Acute Care Hospitals 1 14,937 Total 184 $ 991,218 State # of Properties Gross Investment Texas 16 $ 138,913 Illinois 16 121,755 Ohio 25 110,285 Florida 22 96,249 Pennsylvania 13 42,408 All Others 92 481,608 Total 184 $ 991,218 Primary Tenant # of Properties Gross Investment Lifepoint Health (1) 5 $ 82,337 US HealthVest 3 77,964 GenesisCare 9 31,047 All Others 167 799,870 Total 184 $ 991,218 ____________ (1) During the first quarter of 2023, Everest Rehabilitation assigned its leases to Lifepoint Health on four properties in which the Company had a gross investment totaling $80.7 million at June 30, 2023.

Real Estate Leases (Tables)

Real Estate Leases (Tables)	6 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Schedule of future minimum lease payments for operating leases	Future minimum lease payments under the non-cancelable operating leases due to the Company for the years ending December 31, as of June 30, 2023, are as follows (in thousands): 2023 (six months ended December 31) $ 46,294 2024 89,080 2025 82,644 2026 72,506 2027 66,194 2028 and thereafter 343,830 $ 700,548
Sales-type maturity	Future lease payments due to the Company under this lease for the years ending December 31, as of June 30, 2023, are as follows (in thousands): 2023 (six months ended December 31) $ 170 2024 346 2025 356 2026 367 2027 378 2028 and thereafter 5,210 Total undiscounted lease receivable 6,827 Discount (3,794) Lease receivable $ 3,033
Schedule of operating lease payments	The Company's future lease payments under these non-prepaid ground leases were as follows (in thousands): Operating Financing 2023 (six months ended December 31) $ 21 $ 70 2024 43 154 2025 44 154 2026 44 154 2027 45 154 2028 and thereafter 1,148 6,956 Total undiscounted lease payments 1,345 7,642 Discount (565) (4,364) Lease liabilities $ 780 $ 3,278
Schedule of finance lease payments	The Company's future lease payments under these non-prepaid ground leases were as follows (in thousands): Operating Financing 2023 (six months ended December 31) $ 21 $ 70 2024 43 154 2025 44 154 2026 44 154 2027 45 154 2028 and thereafter 1,148 6,956 Total undiscounted lease payments 1,345 7,642 Discount (565) (4,364) Lease liabilities $ 780 $ 3,278
Ground leases	The following table discloses other information regarding the ground leases. Three Months Ended 2023 2022 Operating leases: Weighted-average remaining lease term in years (including renewal options) 35.7 36.4 Weighted-average discount rate 4.0 % 4.0 % Financing leases: Weighted-average remaining lease term in years (including renewal options) 40.3 36.5 Weighted-average discount rate 4.2 % 4.1 %

Real Estate Acquisitions And _2

Real Estate Acquisitions And Dispositions (Tables)	6 Months Ended
	Jun. 30, 2023
Business Combination and Asset Acquisition [Abstract]
Schedule of acquisitions	The following table summarizes our property acquisitions for the six months ended June 30, 2023: Location Property Type (1) Date Purchase Cash Real Estate Other (2) Square Footage (000's) (000's) (000's) (000's) LaGrange, GA MOB 01/18/23 $ 8,007 $ 8,087 $ 8,118 $ (31) 55,310 West Point, GA MOB 01/18/23 811 819 822 (3) 5,600 Canton, OH MOB 01/30/23 3,669 3,706 4,287 (581) 27,920 Scranton, PA MOB 02/23/23 1,957 2,165 2,317 (152) 22,743 Scranton, PA MOB 02/23/23 2,207 2,366 2,340 26 15,768 LaGrange, GA MOB 03/06/23 6,469 6,458 6,622 (164) 31,473 LaGrange, GA MOB 03/06/23 249 294 300 (6) 2,972 Lakeland, FL Land 04/03/23 838 845 846 (1) — Hermitage, PA MOB 05/04/23 4,218 4,382 4,529 (147) 25,982 San Antonio, TX MOB 05/22/23 2,772 2,783 3,031 (248) 12,376 Clinton, MD MOB 06/21/23 7,850 7,807 7,867 (60) 37,344 $ 39,047 $ 39,712 $ 41,079 $ (1,367) 237,488 (1) MOB - Medical Office Building (2) Includes other assets acquired, liabilities assumed, and above and below-market intangibles recognized at acquisition.
Schedule of assets acquired and liabilities assumed	The following table summarizes the relative fair values of the assets acquired and liabilities assumed in the property acquisitions for the six months ended June 30, 2023. Relative Estimated (in thousands) (in years) Land and land improvements $ 10,051 6.9 Building and building improvements 25,427 23.6 Intangibles: At-market lease intangibles 5,601 3.8 Above-market lease intangibles 481 3.6 Below-market lease intangibles (1,644) 5.9 Total intangibles 4,438 Accounts payable, accrued liabilities and other liabilities assumed (282) Accounts receivable and other assets acquired 242 Prorated rent, interest and operating expense reimbursement amounts collected (164) Total cash consideration $ 39,712

Debt, net (Tables)

Debt, net (Tables)	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Schedule of debt	The table below details the Company's debt as of June 30, 2023 and December 31, 2022. Balance as of (Dollars in thousands) June 30, 2023 December 31, 2022 Maturity Dates Credit Facility: Revolving Credit Facility $ 15,000 $ — 3/26 A-3 Term Loan, net 74,670 74,609 3/26 A-4 Term Loan, net 124,465 124,409 3/28 A-5 Term Loan, net 149,124 149,059 3/30 Mortgage Note Payable, net 4,868 4,920 5/24 $ 368,127 $ 352,997

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of fair value of derivative instruments on balance sheet	The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the Condensed Consolidated Balance Sheets as of June 30, 2023 and December 31, 2022. Asset Derivatives Fair Value at Liability Derivatives Fair Value at (Dollars in thousands) June 30, 2023 December 31, 2022 Balance Sheet Classification June 30, 2023 December 31, 2022 Balance Sheet Classification Interest rate swaps $ 23,085 $ 22,667 Other assets, net $ — $ — Other liabilities, net Offsetting of Derivative Assets (as of June 30, 2023) Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets (In thousands) Gross Amounts of Recognized Assets Gross Amounts Offset in the Condensed Consolidated Balance Sheet Net Amounts of Assets in the Condensed Consolidated Balance Sheets Financial Instruments Cash Collateral Received Net Amount Derivatives $ 23,085 $ — $ 23,085 $ — $ — $ 23,085 Offsetting of Derivative Liabilities (as of June 30, 2023) Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets (In thousands) Gross Amounts of Recognized Liabilities Gross Amounts Offset in the Condensed Consolidated Balance Sheet Net Amounts of Liabilities in the Condensed Consolidated Balance Sheets Financial Instruments Cash Collateral Received Net Amount Derivatives $ — $ — $ — $ — $ — $ — Offsetting of Derivative Assets (as of December 31, 2022) Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets (In thousands) Gross Amounts of Recognized Assets Gross Amounts Offset in the Condensed Consolidated Balance Sheet Net Amounts of Assets in the Condensed Consolidated Balance Sheets Financial Instruments Cash Collateral Received Net Amount Derivatives $ 22,667 $ — $ 22,667 $ — $ — $ 22,667 Offsetting of Derivative Liabilities (as of December 31, 2022) Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets (In thousands) Gross Amounts of Recognized Liabilities Gross Amounts Offset in the Condensed Consolidated Balance Sheet Net Amounts of Liabilities in the Condensed Consolidated Balance Sheets Financial Instruments Cash Collateral Received Net Amount Derivatives $ — $ — $ — $ — $ — $ —
Schedule of derivative Income	The table below details the location in the financial statements of the gain or loss recognized on interest rate derivatives designated as cash flow hedges for the three and six months ended June 30, 2023 and 2022. Three Months Ended Six Months Ended (Dollars in thousands) 2023 2022 2023 2022 Amount of unrealized gain recognized in OCI on derivatives $ 9,875 $ 4,584 $ 4,902 $ 15,991 Amount of (gain) loss reclassified from AOCI into interest expense $ (2,474) $ 635 $ (4,484) $ 1,750 Total interest expense presented in the Condensed Consolidated Statements of Operations in which the effects of the cash flow hedges are recorded $ 4,140 $ 2,755 $ 8,132 $ 5,381

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Schedule of reconciliation of common stock	The following table provides a reconciliation of the beginning and ending common stock balances for the six months ended June 30, 2023 and for the year ended December 31, 2022: (In thousands) Six Months Ended Year Ended Balance, beginning of period 25,897 24,983 Issuance of common stock 485 600 Restricted stock issued 190 318 Restricted stock withheld and forfeited (31) (4) Balance, end of period 26,541 25,897
Schedule of ATM Program	As of June 30, 2023, the Company had approximately $461.5 million remaining that may be issued under the ATM Program. Three Months Ended Six Months Ended Shares issued ( in thousands ) 236 485 Net proceeds received ( in millions) (1) $8.0 $16.9 Average gross sales price per share $34.45 $35.60 ___________ (1) Net proceeds totaling $0.7 million were received on April 3, 2023 relating to shares sold and issued in March 2023.

Net Income (Loss) Per Common _2

Net Income (Loss) Per Common Share (Tables)	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Schedule of net income per share	The following table sets forth the computation of basic and diluted net income (loss) per common share for the three and six months ended June 30, 2023 and 2022, respectively. Three Months Ended Six Months Ended (In thousands, except per share data) 2023 2022 2023 2022 Net income (loss) $ 6,577 $ 5,584 $ (345) $ 11,108 Participating securities' share in earnings (550) (668) (1,373) (1,327) Net income (loss), less participating securities' share in earnings $ 6,027 $ 4,916 $ (1,718) $ 9,781 Weighted average Common Shares outstanding Weighted average Common Shares outstanding 26,358 25,087 26,202 25,074 Unvested restricted shares (1,293) (1,509) (1,554) (1,500) Weighted average Common Shares outstanding–Basic 25,065 23,578 24,648 23,574 Dilutive potential common shares — — — — Weighted average Common Shares outstanding –Diluted 25,065 23,578 24,648 23,574 Basic Net Income (Loss) per Common Share $ 0.24 $ 0.21 $ (0.07) $ 0.41 Diluted Net Income (Loss) per Common Share $ 0.24 $ 0.21 $ (0.07) $ 0.41

Stock Incentive Plan (Tables)

Stock Incentive Plan (Tables)	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Summary of nonvested restricted stock activity	A summary of the activity under the Company's 2014 Incentive Plan, as amended, for the three and six months ended June 30, 2023 and 2022 is included in the table below, as well as compensation expense recognized from the amortization of the value of shares over the applicable vesting periods. Three Months Ended Six Months Ended (Dollars and shares in thousands) 2023 2022 2023 2022 Stock-based awards, beginning of period 1,836 1,502 1,708 1,416 Stock in lieu of compensation 22 8 84 52 Stock awards 39 19 106 67 Total stock granted 61 27 190 119 Vested shares (1) (692) (17) (692) (22) Forfeited shares (2) — (3) (1) Stock-based awards, end of period 1,203 1,512 1,203 1,512 Amortization expense (1) $ 1,692 $ 2,184 $ 16,038 $ 4,307 ___________ (1) Amortization expense for the six months ended June 30, 2023 included the accelerated amortization totaling $11.8 million recognized during the three months ended March 31, 2023, upon the passing of our former CEO and President. These shares vested during the three months ended June 30, 2023.

Other Assets, net (Tables)

Other Assets, net (Tables)	6 Months Ended
	Jun. 30, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of other assets	Other assets, net on the Company's Condensed Consolidated Balance Sheets as of June 30, 2023 and December 31, 2022 are detailed in the table below. Balance as of (Dollars in thousands) June 30, 2023 December 31, 2022 Notes receivable $ 32,435 $ 32,705 Accounts and interest receivable 3,622 2,679 Straight-line rent receivable 17,176 15,429 Prepaid assets 1,685 980 Deferred financing costs, net 577 683 Leasing commissions, net 2,081 1,848 Deferred tax assets, net 221 306 Fair value of interest rate swaps 23,085 22,667 Above-market lease intangible assets, net 2,554 2,399 Sales-type lease receivable 3,033 3,035 Financing right-of-use asset 2,515 2,545 Asset held for sale 1,254 — Operating lease right-of-use assets 744 759 Other 629 496 $ 91,611 $ 86,531
Schedule of VIEs	The VIEs that we have identified at June 30, 2023 are summarized in the table below. Classification Carrying Amount (in thousands) Maximum Exposure to Loss (in thousands) Note receivable (term loan) $ 7,500 $ 7,500 Note receivable (revolving credit facility) $ 5,435 $ 5,435 Note receivable (term loan) $ 17,000 $ 17,000 Note receivable (revolving credit facility) $ 2,500 $ 2,500

Other Liabilities, net (Tables)

Other Liabilities, net (Tables)	6 Months Ended
	Jun. 30, 2023
Other Liabilities Disclosure [Abstract]
Schedule of other liabilities	Other liabilities, net on the Company's Condensed Consolidated Balance Sheets as of June 30, 2023 and December 31, 2022 are detailed in the table below. Balance as of (Dollars in thousands) June 30, 2023 December 31, 2022 Prepaid rent $ 5,579 $ 3,853 Security deposits 3,662 5,766 Below-market lease intangibles, net 2,439 1,075 Financing lease liability 3,278 3,279 Operating lease liability 780 786 Liabilities held for sale 56 — Other 615 478 $ 16,409 $ 15,237

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value, by balance sheet grouping	The table below details the fair values and carrying values for our notes receivable, interest rate swaps, and mortgage note payable at June 30, 2023 and December 31, 2022, using level 2 inputs. June 30, 2023 December 31, 2022 (Dollars in thousands) Carrying Value Fair Value Carrying Value Fair Value Notes receivable $ 32,435 $ 32,604 $ 32,705 $ 32,716 Interest rate swap asset $ 23,085 $ 23,085 $ 22,667 $ 22,667 Mortgage note payable (principal amount) $ 4,884 $ 4,729 $ 4,947 $ 4,761

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details) $ in Thousands, ft² in Millions	Jun. 30, 2023 USD ($) ft² real_estate_property state	Dec. 31, 2022 USD ($)
Accounting Policies [Abstract]
Total real estate properties | $	$ 991,218
Number of real estate properties | real_estate_property	184
Number of properties held for investment in financing lease | real_estate_property	1
Lease receivable | $	$ 3,033	$ 3,035
Number of properties held for sale | real_estate_property	1
Asset held for sale | $	$ 1,254	$ 0
Number of states | state	34
Area of real estate property (in square feet) | ft²	4
Percentage leased	91.70%
Remaining lease term	7 years 1 month 6 days

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Cash and Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Cash and cash equivalents	$ 2,627	$ 11,233	$ 1,699
Restricted cash	1,049	835	659
Cash, cash equivalents and restricted cash	$ 3,676	$ 12,068	$ 2,358	$ 2,867

Real Estate Properties - Additi

Real Estate Properties - Additional Information (Details) ft² in Thousands, $ in Thousands	Jun. 30, 2023 USD ($) ft² real_estate_property	Jun. 27, 2023 ft² lease	Dec. 31, 2022 USD ($)
Real Estate Properties [Line Items]
Total real estate properties | $	$ 991,218
Number of real estate properties	184
Number of properties held for investment in financing lease	1
Lease receivable | $	$ 3,033		$ 3,035
Number of properties held for sale	1
Area of real estate property (in square feet) | ft²	4,000
Percentage leased	91.70%
Held for sale
Real Estate Properties [Line Items]
Disposal property | $	$ 1,300
GenesisCare
Real Estate Properties [Line Items]
Total real estate properties | $	$ 31,047
Number of real estate properties	9
Area of real estate property (in square feet) | ft²	119
Percentage leased	3.10%
GenesisCare | NORTH CAROLINA
Real Estate Properties [Line Items]
Number of leases | lease		1
Area of real estate property (in square feet) | ft²		11
GenesisCare | Sole Tenant Property
Real Estate Properties [Line Items]
Number of real estate properties	7
GenesisCare | Multi-Tenant Property
Real Estate Properties [Line Items]
Number of real estate properties	2

Real Estate Properties - Schedu

Real Estate Properties - Schedule of Real Estate Property Investments (Details) $ in Thousands	Jun. 30, 2023 USD ($) real_estate_property
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	184
Total real estate properties | $	$ 991,218
Lifepoint Health
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	5
Total real estate properties | $	$ 82,337
US HealthVest
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	3
Total real estate properties | $	$ 77,964
GenesisCare
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	9
Total real estate properties | $	$ 31,047
All Others
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	167
Total real estate properties | $	$ 799,870
Everest Rehabilitation
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	4
Total real estate properties | $	$ 80,700
Texas
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	16
Total real estate properties | $	$ 138,913
Illinois
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	16
Total real estate properties | $	$ 121,755
Ohio
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	25
Total real estate properties | $	$ 110,285
Florida
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	22
Total real estate properties | $	$ 96,249
Pennsylvania
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	13
Total real estate properties | $	$ 42,408
All Others
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	92
Total real estate properties | $	$ 481,608
Medical Office Building
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	85
Total real estate properties | $	$ 390,389
Inpatient Rehabilitation Facilities
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	7
Total real estate properties | $	$ 151,234
Acute Inpatient Behavioral
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	5
Total real estate properties | $	$ 130,410
Specialty Centers
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	37
Total real estate properties | $	$ 119,865
Physician Clinics
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	30
Total real estate properties | $	$ 86,602
Surgical Centers and Hospitals
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	10
Total real estate properties | $	$ 52,762
Behavioral Specialty Facilities
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	9
Total real estate properties | $	$ 45,019
Long-term Acute Care Hospitals
Real Estate Properties [Line Items]
Number of real estate properties | real_estate_property	1
Total real estate properties | $	$ 14,937

Real Estate Leases - Future Min

Real Estate Leases - Future Minimum Lease Payments Under Non-cancelable Operating Leases (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Leases [Abstract]
2023 (six months ended December 31)	$ 46,294
2024	89,080
2025	82,644
2026	72,506
2027	66,194
2028 and thereafter	343,830
Total	$ 700,548

Real Estate Leases - Additional

Real Estate Leases - Additional Information (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023 USD ($) real_estate_property lease	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($) real_estate_property lease	Jun. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)
Concentration Risk [Line Items]
Straight line rent	$ 800	$ 900	$ 1,737	$ 1,737
Real estate investment property, net	$ 805,179		$ 805,179		$ 777,826
Number of real estate properties | real_estate_property	184		184
Number of properties held for investment in financing lease | real_estate_property	1		1
Lease receivable	$ 3,033		$ 3,033		$ 3,035
Interest income	$ 100	$ 100	$ 200	$ 200
Number of operating leases | lease	4		4
Number of finance leases | lease	2		2
Four Real Estate Property
Concentration Risk [Line Items]
Real estate investment property, net	$ 43,300		$ 43,300
Number of real estate properties | real_estate_property	12		12

Real Estate Leases - Lease Rece

Real Estate Leases - Lease Receivable (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Leases [Abstract]
2023 (six months ended December 31)	$ 170
2024	346
2025	356
2026	367
2027	378
2028 and thereafter	5,210
Total undiscounted lease receivable	6,827
Discount	(3,794)
Lease receivable	$ 3,033	$ 3,035

Real Estate Leases - Future Lea

Real Estate Leases - Future Lease Payments Under Non-prepaid Ground Leases (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Operating
2023 (six months ended December 31)	$ 21
2024	43
2025	44
2026	44
2027	45
2028 and thereafter	1,148
Total undiscounted lease payments	1,345
Discount	(565)
Lease liabilities	780	$ 786
Financing
2023 (six months ended December 31)	70
2024	154
2025	154
2026	154
2027	154
2028 and thereafter	6,956
Total undiscounted lease payments	7,642
Discount	(4,364)
Lease liabilities	$ 3,278	$ 3,279

Real Estate Leases - Ground Lea

Real Estate Leases - Ground Leases (Details)	Jun. 30, 2023	Jun. 30, 2022
Operating leases:
Weighted-average remaining lease term in years (including renewal options)	35 years 8 months 12 days	36 years 4 months 24 days
Weighted-average discount rate	4%	4%
Financing leases:
Weighted-average remaining lease term in years (including renewal options)	40 years 3 months 18 days	36 years 6 months
Weighted-average discount rate	4.20%	4.10%

Real Estate Acquisitions And _3

Real Estate Acquisitions And Dispositions - Additional Information (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023 USD ($) land_parcel real_estate_property	Mar. 31, 2023 real_estate_property	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)
Business Acquisition [Line Items]
Impairment of real estate assets			$ 1,600
Insurance proceeds from casualty loss			2,273	$ 0
Liabilities held for sale	$ 56		56		$ 0
Interest And Other Income
Business Acquisition [Line Items]
Insurance proceeds from casualty loss			700
Held for sale
Business Acquisition [Line Items]
Disposal property	1,300		1,300
Liabilities held for sale	$ 56		56
Acquisitions Of Properties During Q2 2023
Business Acquisition [Line Items]
Number of real estate properties acquired | real_estate_property	3
Number of land parcel acquired | land_parcel	1
Percentage of properties that were leased at acquisition (in percent)	98.30%
Pro forma information, revenue of acquiree since acquisition date, actual	$ 100
Pro forma information, income of acquiree since acquisition date, actual	32
Transaction costs	$ 400
Acquisitions Of Properties During Q1 2023
Business Acquisition [Line Items]
Number of real estate properties acquired | real_estate_property		7
Percentage of properties that were leased at acquisition (in percent)		100%
Pro forma information, revenue of acquiree since acquisition date, actual			1,300
Pro forma information, income of acquiree since acquisition date, actual			300
Transaction costs			$ 400

Real Estate Acquisitions And _4

Real Estate Acquisitions And Dispositions - Summary of Real Estate Acquisitions (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($) ft²
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Square footage (in square feet) | ft²	4,000,000
Acquisitions Of Properties During Q1 2023 | LaGrange, GA
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase Price	$ 8,007
Cash Consideration	8,087
Real Estate	8,118
Other	$ (31)
Square footage (in square feet) | ft²	55,310
Acquisitions Of Properties During Q1 2023 | West Point, GA
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase Price	$ 811
Cash Consideration	819
Real Estate	822
Other	$ (3)
Square footage (in square feet) | ft²	5,600
Acquisitions Of Properties During Q1 2023 | Canton, OH
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase Price	$ 3,669
Cash Consideration	3,706
Real Estate	4,287
Other	$ (581)
Square footage (in square feet) | ft²	27,920
Acquisitions Of Properties During Q1 2023 | Scranton, PA
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase Price	$ 1,957
Cash Consideration	2,165
Real Estate	2,317
Other	$ (152)
Square footage (in square feet) | ft²	22,743
Acquisitions Of Properties During Q1 2023 | Scranton, PA
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase Price	$ 2,207
Cash Consideration	2,366
Real Estate	2,340
Other	$ 26
Square footage (in square feet) | ft²	15,768
Acquisitions Of Properties During Q1 2023 | LaGrange, GA
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase Price	$ 6,469
Cash Consideration	6,458
Real Estate	6,622
Other	$ (164)
Square footage (in square feet) | ft²	31,473
Acquisitions Of Properties During Q1 2023 | LaGrange, GA
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase Price	$ 249
Cash Consideration	294
Real Estate	300
Other	$ (6)
Square footage (in square feet) | ft²	2,972
Acquisitions Of Properties During Q2 2023 | Lakeland, FL
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase Price	$ 838
Cash Consideration	845
Real Estate	846
Other	$ (1)
Square footage (in square feet) | ft²	0
Acquisitions Of Properties During Q2 2023 | Hermitage, PA
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase Price	$ 4,218
Cash Consideration	4,382
Real Estate	4,529
Other	$ (147)
Square footage (in square feet) | ft²	25,982
Acquisitions Of Properties During Q2 2023 | San Antonio, TX
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase Price	$ 2,772
Cash Consideration	2,783
Real Estate	3,031
Other	$ (248)
Square footage (in square feet) | ft²	12,376
Acquisitions Of Properties During Q2 2023 | Clinton, MD
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase Price	$ 7,850
Cash Consideration	7,807
Real Estate	7,867
Other	$ (60)
Square footage (in square feet) | ft²	37,344
Acquisitions Of Properties During 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase Price	$ 39,047
Cash Consideration	39,712
Real Estate	41,079
Other	$ (1,367)
Square footage (in square feet) | ft²	237,488

Real Estate Acquisitions And _5

Real Estate Acquisitions And Dispositions - Assets Acquired and Liabilities Assumed (Details) - Series of Individually Immaterial Asset Acquisitions $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)
Business Acquisition [Line Items]
Land and land improvements	$ 10,051
Building and building improvements	25,427
Intangibles:
Below-market lease intangibles	$ (1,644)
Below market lease useful life (in years)	5 years 10 months 24 days
Total intangibles	$ 4,438
Accounts payable, accrued liabilities and other liabilities assumed	(282)
Accounts receivable and other assets acquired	242
Prorated rent, interest and operating expense reimbursement amounts collected	(164)
Total cash consideration	39,712
At-market lease intangibles
Intangibles:
Lease intangibles	$ 5,601
Intangibles useful life (in years)	3 years 9 months 18 days
Above-market lease intangibles
Intangibles:
Lease intangibles	$ 481
Intangibles useful life (in years)	3 years 7 months 6 days
Land and land improvements
Business Acquisition [Line Items]
Estimated useful life (in years)	6 years 10 months 24 days
Building and building improvements
Business Acquisition [Line Items]
Estimated useful life (in years)	23 years 7 months 6 days

Debt, net - Schedule of Debt (D

Debt, net - Schedule of Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Debt, net	$ 368,127	$ 352,997
Mortgage Note Payable, net
Debt Instrument [Line Items]
Debt, net	4,868	4,920
Revolving Credit Facility | Line of Credit | Third Amended And Restated Credit Facility
Debt Instrument [Line Items]
Debt, net	15,000	0
A-3 Term Loan, net | Term Loan | Third Amended And Restated Credit Facility
Debt Instrument [Line Items]
Debt, net	74,670	74,609
A-4 Term Loan, net | Term Loan | Third Amended And Restated Credit Facility
Debt Instrument [Line Items]
Debt, net	124,465	124,409
A-5 Term Loan, net | Term Loan | Third Amended And Restated Credit Facility
Debt Instrument [Line Items]
Debt, net	$ 149,124	$ 149,059

Debt, net - Narrative (Details)

Debt, net - Narrative (Details)	Dec. 14, 2022 USD ($) option	Jun. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)
Line of Credit Facility [Line Items]
Amount outstanding		$ 368,127,000	$ 352,997,000
Real estate investment property, net		805,179,000	777,826,000
Mortgage Note Payable, net
Line of Credit Facility [Line Items]
Amount outstanding		$ 4,868,000	4,920,000
Fixed interest rate (in percent)		4.98%
Debt instrument, balloon payment to be paid		$ 4,800,000
Mortgage Note Payable, net | Building
Line of Credit Facility [Line Items]
Real estate investment property, net		6,500,000
Third Amended And Restated Credit Facility | A-5 Term Loan, net | Term Loan
Line of Credit Facility [Line Items]
Face amount	$ 150,000,000
Debt term (in years)	7 years 3 months
Amount outstanding		149,124,000	149,059,000
Third Amended And Restated Credit Facility | Revolving Credit Facility | Line of Credit
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 150,000,000
Number of options to extend | option	1
Length of extension	12 months
Amount outstanding		$ 15,000,000	0
Weighted average interest rate percentage		6.80%
Remaining borrowing capacity		$ 135,000,000
Third Amended And Restated Credit Facility | Revolving Credit Facility | Line of Credit | SOFR | Minimum
Line of Credit Facility [Line Items]
Variable rate percentage	1.25%
Third Amended And Restated Credit Facility | Revolving Credit Facility | Line of Credit | SOFR | Maximum
Line of Credit Facility [Line Items]
Variable rate percentage	1.90%
Third Amended And Restated Credit Facility | Revolving Credit Facility | Line of Credit | Base Rate | Minimum
Line of Credit Facility [Line Items]
Variable rate percentage	0.25%
Third Amended And Restated Credit Facility | Revolving Credit Facility | Line of Credit | Base Rate | Maximum
Line of Credit Facility [Line Items]
Variable rate percentage	0.90%
Third Amended And Restated Credit Facility | Term Loan | Line of Credit
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 350,000,000
Third Amended And Restated Credit Facility | A-2 Term Loan, net | Term Loan
Line of Credit Facility [Line Items]
Face amount	$ 50,000,000
Debt term (in years)	7 years
Third Amended And Restated Credit Facility | Credit Facility, Accordion Feature
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 700,000,000
Third Amended And Restated Credit Facility | A-3 Term Loan, net | Term Loan
Line of Credit Facility [Line Items]
Face amount	$ 75,000,000
Debt term (in years)	7 years
Amount outstanding		74,670,000	74,609,000
Third Amended And Restated Credit Facility | A-4 Term Loan, net | Term Loan
Line of Credit Facility [Line Items]
Face amount	$ 125,000,000
Debt term (in years)	7 years
Amount outstanding		124,465,000	$ 124,409,000
Third Amended And Restated Credit Facility | Revolving Credit Facility, Unused Borrowing Capacity Rate 1 | Line of Credit
Line of Credit Facility [Line Items]
Unused borrowing commitment fee percentage	0.20%
Percentage of borrowing capacity outstanding	33.30%
Third Amended And Restated Credit Facility | Revolving Credit Facility, Unused Borrowing Capacity Rate 2 | Line of Credit
Line of Credit Facility [Line Items]
Unused borrowing commitment fee percentage	0.25%
Percentage of borrowing capacity outstanding	33.30%
First Amended And Restated Credit Facility | Term Loan
Line of Credit Facility [Line Items]
Amount outstanding		$ 350,000,000
Weighted average interest rate percentage		4.30%
First Amended And Restated Credit Facility | Term Loan | SOFR | Minimum
Line of Credit Facility [Line Items]
Variable rate percentage	1.45%
First Amended And Restated Credit Facility | Term Loan | SOFR | Maximum
Line of Credit Facility [Line Items]
Variable rate percentage	2.30%
First Amended And Restated Credit Facility | Term Loan | Base Rate | Minimum
Line of Credit Facility [Line Items]
Variable rate percentage	0.45%
First Amended And Restated Credit Facility | Term Loan | Base Rate | Maximum
Line of Credit Facility [Line Items]
Variable rate percentage	1.30%

Derivative Financial Instrume_3

Derivative Financial Instruments - Narrative (Details) $ in Millions	6 Months Ended
	Jun. 30, 2023 USD ($) derivative_instrument
Derivative [Line Items]
Cash flow hedges reclassified to interest expense	$ 10.5
Cash Flow Hedging | Interest Rate Contract
Derivative [Line Items]
Number outstanding interest rate derivatives | derivative_instrument	17
Notional amount	$ 350
Cash Flow Hedging | Interest Rate Swap
Derivative [Line Items]
Number outstanding interest rate derivatives | derivative_instrument	2
Notional amount	$ 50

Derivative Financial Instrume_4

Derivative Financial Instruments - Fair Value Balance Sheet (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Derivatives, Fair Value [Line Items]
Interest rate swap asset	$ 23,085	$ 22,667
Interest rate swap liability	$ 0	$ 0
Derivative Asset, Statement of Financial Position [Extensible Enumeration]	Other assets, net	Other assets, net
Derivative Liability, Statement of Financial Position [Extensible Enumeration]	Other liabilities, net	Other liabilities, net
Cash Flow Hedging | Interest rate swaps | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Interest rate swap asset	$ 23,085	$ 22,667
Interest rate swap liability	$ 0	$ 0

Derivative Financial Instrume_5

Derivative Financial Instruments - Cash Flow Hedging (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Interest Expense	Interest Expense	Interest Expense	Interest Expense
Interest Rate Contract | Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of unrealized gain recognized in OCI on derivatives	$ 9,875	$ 4,584	$ 4,902	$ 15,991
Total interest expense presented in the Condensed Consolidated Statements of Operations in which the effects of the cash flow hedges are recorded	4,140	2,755	8,132	5,381
Interest Rate Contract | Cash Flow Hedging | Interest Expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of (gain) loss reclassified from AOCI into interest expense	$ (2,474)	$ 635	$ (4,484)	$ 1,750

Derivative Financial Instrume_6

Derivative Financial Instruments - Offsetting of Derivative Assets and Liability (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Derivative Asset [Abstract]
Gross Amounts of Recognized Assets	$ 23,085	$ 22,667
Gross Amounts Offset in the Condensed Consolidated Balance Sheet	0	0
Net Amounts of Assets in the Condensed Consolidated Balance Sheets	23,085	22,667
Gross amounts not offset in the condensed Consolidated balance sheets, financial instruments	0	0
Gross amounts not offset in the condensed consolidated balance sheets, net amount	0	0
Gross amounts not offset in the condensed consolidated balance sheets, cash collateral received	23,085	22,667
Derivative Liability [Abstract]
Gross Amounts of Recognized Liabilities	0	0
Gross Amounts Offset in the Condensed Consolidated Balance Sheet	0	0
Net Amounts of Liabilities in the Condensed Consolidated Balance Sheets	0	0
Gross amounts not offset in the condensed consolidated balance sheets, financial instruments	0	0
Gross amounts not offset in the condensed consolidated balance sheets, cash collateral received	0	0
Gross amounts not offset in the condensed consolidated balance sheets, net amount	$ 0	$ 0

Stockholders' Equity - Reconcil

Stockholders' Equity - Reconciliation of Common Stock (Details) - shares shares in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance, beginning of period (in shares)	25,897	24,983
Issuance of common stock, net of issuance costs (in shares)	485	600
Restricted stock issued (in shares)	190	318
Restricted stock withheld and forfeited (in shares)	(31)	(4)
Balance, end of period (in shares)	26,541	25,897

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details) - At The Market Offering Program - Common Stock $ in Millions	6 Months Ended
	Jun. 30, 2023 USD ($)
Subsidiary, Sale of Stock [Line Items]
Value of shares authorized	$ 500
Shares available for issuance (in shares)	$ 461.5

Stockholders' Equity - ATM Prog

Stockholders' Equity - ATM Program (Details) - Common Stock - At The Market Offering Program - USD ($) $ / shares in Units, shares in Thousands, $ in Millions		3 Months Ended	6 Months Ended
	Apr. 03, 2023	Jun. 30, 2023	Jun. 30, 2023
Class of Stock [Line Items]
Sale of stock, number of shares issued in transaction (in shares)		236	485
Net proceeds received	$ 0.7	$ 8	$ 16.9
Average gross sales price per share (in dollars per share)		$ 34.45	$ 35.60

Net Income (Loss) Per Common _3

Net Income (Loss) Per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Earnings Per Share [Abstract]
Net income (loss)	$ 6,577	$ 5,584	$ (345)	$ 11,108
Participating securities' share in earnings	(550)	(668)	(1,373)	(1,327)
Net income (loss), less participating securities' share in earnings	$ 6,027	$ 4,916	$ (1,718)	$ 9,781
Weighted average Common Shares outstanding
Weighted average common shares outstanding (in shares)	26,358	25,087	26,202	25,074
Unvested restricted shares (in shares)	(1,293)	(1,509)	(1,554)	(1,500)
Weighted average common shares outstanding – basic (in shares)	25,065	23,578	24,648	23,574
Dilutive potential common share (in shares)	0	0	0	0
Weighted average common shares outstanding –diluted (in shares)	25,065	23,578	24,648	23,574
Basic net income (loss) per common share (in dollars per share)	$ 0.24	$ 0.21	$ (0.07)	$ 0.41
Diluted net income (loss) per common share (in dollars per share)	$ 0.24	$ 0.21	$ (0.07)	$ 0.41

Stock Incentive Plan (Details)

Stock Incentive Plan (Details) - USD ($) $ in Thousands		3 Months Ended			6 Months Ended
	Mar. 03, 2023	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Stock-based awards:
Stock-based compensation expense					$ 16,000	$ 4,300
Accelerated amortization of stock-based compensation					$ 11,799	$ 0
Restricted Common Stock | Former CEO and President
Stock-based awards:
Accelerated amortization of stock-based compensation			$ 11,800
Share based payment award, accelerated vesting (in shares)	624,725
2014 Incentive Plan | Restricted Common Stock
Stock-based awards:
Stock-based awards, beginning of period (in shares)		1,836,000	1,708,000	1,502,000	1,708,000	1,416,000
Granted (in shares)		61,000		27,000	190,000	119,000
Vested (in shares)		(692,000)		(17,000)	(692,000)	(22,000)
Forfeited (in shares)		(2,000)		0	(3,000)	(1,000)
Stock-based awards, end of period (in shares)		1,203,000	1,836,000	1,512,000	1,203,000	1,512,000
Stock-based compensation expense		$ 1,692		$ 2,184	$ 16,038	$ 4,307
2014 Incentive Plan | Stock in lieu of compensation
Stock-based awards:
Granted (in shares)		22,000		8,000	84,000	52,000
2014 Incentive Plan | Stock awards
Stock-based awards:
Granted (in shares)		39,000		19,000	106,000	67,000

Other Assets, net - Other Asset

Other Assets, net - Other Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Notes receivable	$ 32,435	$ 32,705
Accounts and interest receivable	3,622	2,679
Straight-line rent receivable	17,176	15,429
Prepaid assets	1,685	980
Deferred financing costs, net	577	683
Leasing commissions, net	2,081	1,848
Deferred tax assets, net	221	306
Fair value of interest rate swaps	23,085	22,667
Above-market lease intangible assets, net	2,554	2,399
Sales-type lease receivable	3,033	3,035
Financing right-of-use asset	2,515	2,545
Asset held for sale	1,254	0
Operating lease right-of-use assets	744	759
Other	629	496
Other assets, net	$ 91,611	$ 86,531

Other Assets, net - Narrative (

Other Assets, net - Narrative (Details)	6 Months Ended
	Jun. 30, 2023 USD ($) hospital	Dec. 31, 2022 USD ($)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Notes receivable	$ 32,435,000	$ 32,705,000
Note receivable (term loan) | Variable Interest Entity, Not Primary Beneficiary
Accounts, Notes, Loans and Financing Receivable [Line Items]
Notes receivable	$ 7,500,000
Notes Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Note receivable interest rate	9%
Additional funding	$ 5,000,000
Non-cash interest rate	3%
Notes Receivable | Note receivable (term loan)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Notes receivable	$ 7,500,000	9,000,000
Payment received	$ 250,000
Note receivable interest rate	9%
Notes Receivable | Note receivable (revolving credit facility)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Payment received	$ 40,000
Note receivable (term loan) | Variable Interest Entity, Not Primary Beneficiary
Accounts, Notes, Loans and Financing Receivable [Line Items]
Notes receivable	17,000,000	17,000,000
Note receivable (revolving credit facility) | Variable Interest Entity, Not Primary Beneficiary
Accounts, Notes, Loans and Financing Receivable [Line Items]
Notes receivable	5,435,000	5,000,000
Note receivable (revolving credit facility) | Variable Interest Entity, Not Primary Beneficiary
Accounts, Notes, Loans and Financing Receivable [Line Items]
Notes receivable	$ 2,500,000	$ 1,700,000
Long-Term Acute Care Hospitals | Note receivable (term loan)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of properties used to secure notes by borrower | hospital	7
Inpatient Rehabilitation Facilities | Note receivable (term loan)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of properties used to secure notes by borrower | hospital	1
Geriatric Behavioral Hospital
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of properties used to secure notes by borrower | hospital	6
Revolving Credit Facility | Notes Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Note receivable interest rate	9%
Revolving Credit Facility | Note receivable (revolving credit facility)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Note receivable interest rate	9%
Non-cash interest rate	3%

Other Assets, net - VIEs (Detai

Other Assets, net - VIEs (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Variable Interest Entity [Line Items]
Carrying amount	$ 32,435	$ 32,705
Variable Interest Entity, Not Primary Beneficiary | Note receivable (term loan)
Variable Interest Entity [Line Items]
Carrying amount	7,500
Maximum exposure to loss	7,500
Variable Interest Entity, Not Primary Beneficiary | Note receivable (revolving credit facility)
Variable Interest Entity [Line Items]
Carrying amount	5,435	5,000
Maximum exposure to loss	5,435
Variable Interest Entity, Not Primary Beneficiary | Note receivable (term loan)
Variable Interest Entity [Line Items]
Carrying amount	17,000	17,000
Maximum exposure to loss	17,000
Variable Interest Entity, Not Primary Beneficiary | Note receivable (revolving credit facility)
Variable Interest Entity [Line Items]
Carrying amount	2,500	$ 1,700
Maximum exposure to loss	$ 2,500

Other Liabilities, net (Details

Other Liabilities, net (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Other Liabilities Disclosure [Abstract]
Prepaid rent	$ 5,579	$ 3,853
Security deposits	3,662	5,766
Below-market lease intangibles, net	$ 2,439	$ 1,075
Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]	Other liabilities, net	Other liabilities, net
Financing lease liability	$ 3,278	$ 3,279
Operating lease, liability, statement of financial position	Other liabilities, net	Other liabilities, net
Operating lease liability	$ 780	$ 786
Liabilities held for sale	56	0
Other	615	478
Other liabilities, net	$ 16,409	$ 15,237

Fair Value of Financial Instr_3

Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Notes receivable	$ 32,435	$ 32,705
Interest rate swap asset	23,085	22,667
Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Notes receivable	32,435	32,705
Mortgage note payable (principal amount)	4,884	4,947
Carrying Value | Interest rate swaps
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Interest rate swap asset	23,085	22,667
Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Notes receivable	32,604	32,716
Mortgage note payable (principal amount)	4,729	4,761
Fair Value | Interest rate swaps | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Interest rate swap asset	$ 23,085	$ 22,667

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event $ / shares in Units, $ in Millions		1 Months Ended
	Jul. 27, 2023 $ / shares	Aug. 01, 2023 USD ($) real_estate_property
Subsequent Event [Line Items]
Dividend declared (in dollars per share) | $ / shares	$ 0.4525
Aggregate purchase price | $		$ 35.6
Total cash consideration | $		$ 35.7
Percentage of properties that were leased at acquisition (in percent)		100%
Medical Office Building
Subsequent Event [Line Items]
Number of real estate properties acquired | real_estate_property		3
Inpatient Rehabilitation Facilities
Subsequent Event [Line Items]
Number of real estate properties acquired | real_estate_property		1